# Interleukin- 17 (IL-17), Bcl-3, and NF-kappa-B Inhibitor Zeta (IκBζ) Expression Levels in the Psoriasis Patients

> **NCT06408454** · — · COMPLETED · sponsor: **Kahramanmaras Sutcu Imam University** · enrollment: 12 (actual)

## Conditions studied

- Psoriasis
- Periodontal Diseases

## Interventions

- **DIAGNOSTIC_TEST:** Gingival crevicular fluid collection
- **DIAGNOSTIC_TEST:** periodontal test

## Key facts

- **NCT ID:** NCT06408454
- **Lead sponsor:** Kahramanmaras Sutcu Imam University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-01
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-08-15
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06408454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06408454, "Interleukin- 17 (IL-17), Bcl-3, and NF-kappa-B Inhibitor Zeta (IκBζ) Expression Levels in the Psoriasis Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06408454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*